ARTICLE | Deals
Antithrombotic comes back to Novartis via deal for Blackstone-backed Anthos
Pharma had held minority stake in 2019 spinout of mAb, now in Phase III for atrial fibrillation and cancer-associated thrombosis
February 12, 2025 1:25 AM UTC
Novartis’ deal to acquire Anthos will give the pharma full control of an antithrombotic program it had spun out in 2019, ending an arrangement in which Blackstone Life Sciences had backed the company.
The agreement comes 10 months after Anthos named Bill Meury CEO; Meury joined the biotech after a stint as CEO of Karuna Therapeutics Inc., during which he steered the company into its $14 billion sale to Bristol Myers Squibb Co. (NYSE:BMY) less than a year after his arrival. Anthos had been led by CEO John Glasspool from its inception until that point...